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Summary We have analysed 15 infiltrating duct carcinomas of the breast, 10 gastrointestinal adenocar-
cinomas, one each of the thyroid and larynx, and four mesenchymal tumours for the presence and the nature
of procoagulant activity (PCA). The metastatic tumours had a significantly higher PCA (P = 0.01-0.001) as
compared to the non-metastatic tumours in the respective groups, and almost 20-25 times the activity as
comnpared to normal tissue (P = 0.001). Although the majority of the tumours had FVII-dependent tissue
thromboplastin-like activity, some of the tumour homogenates revealed the presence of an FVII-independent
PCA. Unlike the known alternate PCA, which acts via factor X activation, this PCA was factor X
independent. It caused clot formation in FX-deficient plasma (six cases) and purified fibrinogen solution (four
cases), indicating the presence of a Xa-like enzyme or a thrombin-like activity respectively.
As early as 1938, Sproule recognised the association between
malignancy and alterations in haemostasis. Since then, it is
well known that malignant disease is associated with a high
incidence of vascular thrombosis or disseminated intravas-
cular coagulation (Rickles & Edwards, 1983). Deposition of
fibrin within and around the tumour has been convincingly
demonstrated immunohistochemically and ultrastructurally
(Rickles & Edwards, 1983) but its precise role in the growth
and spread of the tumour is largely unknown. O'Meara
(1958) first described the procoagulant activity of cancer
cells. PCA could be present at the cancer cell surface or
secreted by it, and may be of two types: (a) FVII-dependent,
tissue thromboplastin activity (Rickles & Edwards, 1983;
Markus, 1984; Cajot et al., 1986); (b) FVII-independent,
direct FX activator (Curatolo et al., 1979; Hilgard & Whur,
1980; Gordon & Cross, 1981). Whatever may be the nature
of PCA, it triggers the formation of microthrombi at the
surface of circulating tumour cells, thereby facilitating the
early implantation of single or aggregated tumour cells in the
microcirculation of various organs and thus establishing
metastasis.
In this study, we have found that the metastatic tumours
have a higher PCA than their non-metastatic counterparts or
normal tissue, and for the first time have demonstrated the
presence of FXa and a thrombin-like PCA in some of the
tumours.
Materials and methods
Collection andprocessing of tumours
Tumour samples were collected in autoclaved normal saline
immediately after resection or biopsy in the operation
theatre, and delivered to the laboratory within 15 min of
collection. Each tissue was washed several times with normal
saline to remove blood and other tissue fluids, minced and
then homogenised in a tissue homogeniser with a tight pestle.
The homogenate was centrifuged at 8000g for 30min and
non-homogenisable tissue debris discarded. The protein con-
tent of the supernatant was estimated by Lowry's method
and the sample was stored at - 20'C until further analysis.
The tissue samples included: infiltrating duct carcinoma of
the breast, 15 (nine metastatic and six non-metastatic);
adenocarcinoma of the gastrointestinal tract (GIT), 10 (seven
metastatic and three non-metastatic); ovarian carcinomas,
four (all metastatic); papillary carcinoma of the thyroid, one;
squamous cell carcinoma of larynx, one; malignant fibrous
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histiocytoma, one; angiofibroma, two; and dermatofibro-
sarcoma, one. In addition two samples of normal breast,
three of normal ovary and three inflammatory lesions of GIT
were also collected.
The tumour homogenate (TH) was thawed immediately
before use and diluted in normal saline to a final protein
concentration of I mg ml' before use in coagulation studies.
Assay ofPCA
Plasma recalcification time was noted after addition of
0.1 ml TH to 0.1 ml of normal pooled plasma. This was
compared with a standard tissue thromboplastin calibration
curve established by plotting various dilutions of human
brain thromboplastin (HBT) against clotting times on a
bilogarithmic scale. The clotting time obtained with
I mgml-' protein concentration of HBT was taken to repre-
sent 100% PCA. Tumour PCA was thus expressed as %
activity of HBT.
Nature ofPCA
In order to establish the mechanism of interaction of tumour
PCA with the coagulation system, 0.1 ml of TH was
incubated with 0.1 ml each of FVII-deficient (Diagen), FVIII-
deficient (known severe haemophiliac) and FX-deficient
(Diagen) plasmas respectively, and recalcification time noted
after addition of 0.025 M CaC12. Clotting time of a mixture of
substrate plasma, normal saline and calcium chloride was
taken to represent basal thromboplastin generation within
the test system, while shortening of the above recalcification
time with the addition of TH indicated the presence of
bypassing activity. FX bypassing activity was expressed in
units of FXaml-' by using commercial FXa (Diagen) with
an activity of 1.25 u ml-' as standard. TH having FX bypass-
ing activity were tested for any direct clotting action on
purified bovine fibrinogen (Sigma). A total of 0.1 ml of TH
was incubated with 0.2 ml fibrinogen (2 mgml') and the
mixture was observed for any clot formation. Clotting times
of fibrinogen (2 mgml-') with commercial thrombin
(Diagen) in concentrations varying from 1 to 50 uml-' were
noted and a calibration curve plotted on a bilogarithmic
graph. From the clotting time of TH with fibrinogen, the
direct clotting activity (thrombin-like) was expressed in terms
of thrombin units.
Statistical analysis was performed by applying Student's
t test.
Results
PCA ofbreast tumours
The mean PCA of metastatic infiltrating duct carcinoma was
76.1% (range 15-150% ofHBT) and was significantly higher
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(P = 0.01) as compared to the mean PCA of non-metastatic
carcinomas (11.3%; range 0-35% of HBT). In the majority
of cases PCA was FVII-dependent and FVIII-independent.
Three out of nine metastatic tumours contained FX bypass-
ing activity, and one of these three had thrombin-like activity
of 10 u ml-'. None of the non-metastatic carcinomas
revealed an FX-bypassing activity. Two samples of normal
breast tissue had a PCA of 4 and 2.5% respectively. (See
Table I.)
PCA ofGIT tumours
The mean PCA of metastatic adenocarcinoma was 120.5%,
the range being 86-170% of HBT, and was significantly
higher (P = 0.001) than the non-metastatic adenocarcinomas,
which had a mean PCA of 7.7% with a range of 2.3-10.5%.
PCA was largely FVII-dependent. FX-bypassing activity was
present in one of three non-metastatic adenocarcinomas
which was thrombin-like and equivalent to 4.7 u ml-'. These
activities were not demonstrable in any of the metastatic
tumours. (See Table II.)
Tissue samples taken from three GIT inflammatory lesions
had a mean PCA of 22% (range 10.5-45%), which was also
FVII-dependent. FX-bypassing activity was not detected. The
mean PCA of metastatic adenocarcinoma was significantly
higher (P = 0.001) than the mean PCA of inflammatory
lesions.
PCA ofovarian tumours
The mean PCA of four metastatic ovarian carcinomas (two
serous and two mucinous) was 112.5% with a range of
56-170% of HBT. FX-bypassing, Xa-like activity was
detected in two of four carcinomas. PCA of three normal
ovarian tissues ranged between 3 and 9%, the mean value
being 6%, which was significantly lower (P = 0.001) than the
mean PCA of metastatic carcinomas. (See Table III.)
PCA ofmesenchymal tumours
Samples taken from two cases of angiofibroma had PCA of
1.7% and 17% respectively, one case of dermato-
fibrosarcoma had PCA of 8% and TH from a specimen of
malignant fibrous histiocytoma showed a PCA of 1.6%. FX-
bypassing activity was present in one case of angiofibroma
Table I Procoagulant activity of infiltrating duct carcinoma
breast
Procoagulant
activity* FXBPA Thrombin-like
(% of HBT) (Xa uml-') activity (uml-')
Metastatic
1 84 0 0
2 75 0 0
3 64 0 0
4 46 0 0
5 53 0 0
6 94 0.0001 0
7 104 0.005 0
8 150 0 0
9 15 0.0312 10
Non-metastatic
1 8.5 0 0
2 35.0 0 0
3 7.5 0 0
4 0.0 0 0
5 14.5 0 0
6 2.3 0 0
Normal-tissue
1 4.0 0 0
2 2.5 0 0
HBT, human brain thromboplastin; FXBPA, FX-bypassing activity;
*P value A versus B=0.01.
Table II Procoagulant activity of GIT tumours and inflammatory
lesions
Procoagulant Thrombin-like
activity* FXBPA activity
(% of HBT) (Xa uml-') (uml-')
Metastatic
1 Adenocarcinoma colon 86 0 0
2 Adenocarcinoma colon 112 0 0
3 Adenocarcinoma colon 110 0 0
4 Adenocarcinoma rectum 150 0 0
5 Adenocarcinoma stomach 106 0 0
6 Adenocarcinoma stomach 110 0 0
7 Adenocarcinoma stomach 170 0 0
Non-metastatic
I Adenocarcinoma colon 2.3 0 0
2 Adenocarcinoma colon 10.5 0 0
3 Adenocarcinoma colon 10.5 0.0117 4.7
Inflammatory lesions
1 Tubercular enteritis 10.5 0 0
2 Acute non-specific 10.5 0 0
enteritis
3 Chronic cholecystitis 45.0 0 0
HBT, human brain thromboplastin; FXBPA, FX-bypassing activity;
*P value A versus B and C = 0.001.
Table III Procoagulant activity of ovarian tumours and normal
tissue
Procoagulant Thrombin-like
activity* FXBPA activity
(% of HBT) (Xa uml-') (urml-')
Metastatic
I Adenocarcinoma ovary 114 0.0003 0
2 Adenocarcinoma ovary 56 0 0
3 Adenocarcinoma ovary 170 0 0
4 Adenocarcinoma ovary 110 0.0009 0
Normal ovaries
1 6 0 0
2 9 0 0
3 3 0 0
HBT, human brain thromboplastin; FXBPA, FX-bypassing activity;
*P value A versus B = 0.001.
(Xa-like) and malignant fibrous histiocytoma (thrombin-like).
(See Table IV.)
Apart from these tumours, one case each of papillary
carcinoma thyroid (metastatic) and squamous cell carcinoma
of larynx (metastatic) were studied. Papillary carcinoma of
thyroid had a PCA of 23% and showed an FX-bypassing
thrombin-like activity equivalent to 10uml-'. Carcinoma
larynx had a PCA of 110% and possessed Xa-like property
(0.022 Xa u ml-').
Discussion
Local deposition of fibrin (Cajot et al., 1986) and generalised
activation of blood coagulation (Bick, 1978) are frequently
observed in experimental animals and patients with malig-
nant tumours. Fibrin mesh-work helps in tumour cell
embolisation and thus formation of distant metastasis. The
ability of tumour cells to form fibrin is related to the
Table IV Procoagulant activity of mesenchymal tumours
Procoagulant Thrombin-like
activity FXBPA activity
(% of HBT) (Xa uml') (um-')
I Angiofibroma 17.0 0.0002 0
2 Angiofibroma 1.7 0 0
3 Dermatofibrosarcoma 7.5 0 0
4 Malignant fibrous 1.6 0.0234 11
histiocytoma
(non-metastatic)
HBT, human brain thromboplastin; FXBPA, FX-bypassing activity.Xa AND THROMBIN-LIKE PCA 31
presence of tumour procoagulant activity (Cajot et al., 1986).
The PCA is largely tissue thromboplastin-like, being FVII-
dependent, although alternate mechanisms which involve
direct FX activation exist (Hilgard & Whur, 1980; Gordon &
Cross, 1981). Zacharski et al. (1987) have reported the occur-
rence of thrombin-generated cleavage sites of human
fibrinogen within the connective tissue stroma adjacent to
viable tumour cells in fresh frozen sections of small cell
carcinoma of lung by means of immunohistochemistry,
thereby providing indirect evidence of thrombin in tumour
cells. In our study of human malignant tumours an attempt
was made to correlate metastatic potential with the amount
of PCA and also to categorise the functional types of PCA
from tumours of varied histogenesis.
Initially, the occurrence of PCA was described in tissue
homogenates. In recent studies utilising cell culture systems
the presence of intracellular, membrane-bound and extracel-
lularly released PCA was confirmed (Rickles & Edwards,
1983; Cajot et al., 1986). Tumour homogenate is a
heterogenous mixture containing factors from tumour cells,
solubilised extracellular matrix and endothelial cells from the
vascular framework. Tumour cell related activity in tumour
homogenate is best expressed in relation to the DNA content
or cell numbers. However, in our study PCA of tumour
homogenates was expressed in terms of protein concentration
of the homogenate. Thus the origin of PCA from tumour/
endothelial cells cannot be established with certainty. A his-
topathological examination of each tumour specimen with
special emphasis on cellularity, matrix, vascularisation, nec-
rosis and inflammatory reaction was performed, and tumours
with significant areas of necrosis or stromal reaction were
excluded from the analysis.
In general PCA of malignant metastatic tumours was
higher compared to their respective non-metastatic counter-
parts, inflammatory lesions and normal tissue. The mean
PCA of metastatic adenocarcinoma of gut was 15-fold higher
compared to the non-metastatic adenocarcinoma (120.5%
versus 7.7%), but only five times more than gut
inflammatory lesions (120.5% versus 22%). However, in both
situations the difference was significant (P = 0.001). The
PCA of inflammatory tissue is released from granulocytes,
macrophages and endothelial cells. Fibrin is an important
component of inflammatory granulation tissue, forming a
scaffold for capillary network and fibroblastic proliferation.
PCA of metastatic breast tumour was seven-fold higher than
of non-metastatic carcinomas (76.1% versus 11.3%,
P = 0.01) and almost 25 times more than normal breast
tissue (76.1% versus 3.2%, P = 0.001). Similar observations
were made as regards PCA of metastatic ovarian carcinoma
versus normal ovarian tissue (112.5% versus 6%, P = 0.001).
Thus significantly higher amounts of PCA correlates with the
metastatic potential of the tumours.
The PCA of the majority of tumours and both
inflammatory and normal tissue was tissue thromboplastin-
like, i.e. exerting its effect by FVII activation. All TH
bypassed FVIII deficiency, thus indicating that the intrinsic
pathway activation does not contribute to tumour cell
induced fibrin formation. Some of the TH even bypassed the
need for FX, indicating the presence of an already existing
Xa or thrombin-like enzymes. Normal and inflammatory
tissues lacked any FX-bypassing activity. In two of six meta-
static tumours and two of three non-metastatic tumours, the
FX bypassing activity was categorised as a thrombin-like
enzyme converting fibrinogen directly to fibrin. In the rest of
the tumours with FX-bypassing activity, PCA appears to be
an Xa-like enzyme.
The association between the presence of FX-bypassing
activity and metastatic potential of malignant tumours can-
not be delineated from the above observations. Xa and
thrombin-like enzymes may represent some of the proteins
synthesised due to aberrant metabolism of neoplastic cells,
and if present may provide the tumour cells with alternate
pathways for fibrin formation. In conclusion, it can be stated
that the increased amount of thromboplastin-like PCA is
distinctly associated with tumour dissemination, and re-
affirms the necessity of fibrin for tumour metastasis although
the cell of origin of PCA in TH can only be ascertained using
cell cultures. In addition we have for the first time demon-
strated an FX-independent PCA of tumour cells, Xa and
thrombin-like activities, although the biological significance
of this remains to be elucidated.
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